Microbes are widely used in pharmaceutical, pesticides, food industry, energy, and a series of innovative applications. Through the research on microbe genome, functional genes related with new special enzyme, important metabolic processes, and metabolite are constantly being discovered and applied to production as well as the transformation of traditional industry and technology. It has a certain value in the application of bio-pharmaceutics, pollution control, energy, chemical, and biological manufacturing industries. Early strain transformation mainly concentrate on random screening and simple rational screening, but the disadvantages which included time-consuming, laborious, and heavy workload and no orientation of mutagenesis in traditional methods were gradually exposed as time went on. With the development of modern molecular biology techniques, many new methods for strains breeding appeared with directionality and positive mutation. The emergence of CRISPR-Cas9 technology has greatly promoted the accuracy and efficiency of microbe genome editing.
- Cloning sequencing
- NGS and analysis
- Customized genome sgRNA design
- Vector synthesis and construction of customized sgRNA and Cas protein, to achieve tandem assembly in 8 sgRNAs at most
- Design and synthesis of donor Vector
- Genome editing of Saccharomyces cerevisiae
- Genome editing for other strains (please consult technicians)
- Sequencing verification
- One-stop Service
Synbio Technologies provides complete solutions from sgRNA design, synthesis and vector construction to microbe genome editing.
- Patented Technology Platform|
Synbio Technologies has patented sgRNA design software that provides efficient and accurate design for multiple species.
- Syno® 2.0 Gene Synthesis Platform
The sgRNA and Cas9 vector can be customized to achieve tandem assembly in 8 sgRNAs at most.
.Jiang Y, Chen B, Duan C, et al. Multigene editing in the Escherichia coli genome via the CRISPR-Cas9 system[J]. Applied and environmental microbiology,2015, 81(7): 2506-2514.
.Huang G, Zang B, Wang X, et al. Encapsulated paclitaxel nanoparticles exhibit enhanced anti-tumor efficacy in A549 non-small lung cancer cells[J]. Actabiochimica et biophysica Sinica, 2015, 47(12): 981-987.